SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine
- vacsaín nanacháithníní spícephróitéine athchuingreach SARS-CoV-2 Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
- ga
- SARS-CoV-2 recombinant spike protein nanoparticle vaccine
- en
- Sainmhíniú recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant Tagairt "Cheryl Keech, M.D., Ph.D., Gary Albert, M.S., Iksung Cho, M.S., Andreana Robertson, M.S., Patricia Reed, B.S., Susan Neal, Joyce S. Plested, Ph.D., Mingzhu Zhu, Ph.D., Shane Cloney-Clark, B.S., Haixia Zhou, Ph.D., Gale Smith, Ph.D., Nita Patel, M.S., Matthew B. Frieman, Ph.D., Robert E. Haupt, M.S., James Logue, B.A., Marisa McGrath, B.A., Stuart Weston, Ph.D., Pedro A. Piedra, M.D., Chinar Desai, B.S., Kathleen Callahan, M.S., Maggie Lewis, M.S., Patricia Price-Abbott, M.S., Neil Formica, M.B., B.S., Vivek Shinde, M.D., Louis Fries, M.D., Jason D. Lickliter, M.B., B.S., Ph.D., Paul Griffin, M.D., Bethanie Wilkinson, Ph.D., and Gregory M. Glenn, M.D., 'Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine' (18.6.2021), New England Journal of Medicine 2020; 383:2320-2332"
- NVX-CoV2373
- mul